Evidence map›Paper›PMID 37938564›Full record

ArticleCell death & disease2023

SCF

Juliana Haydeé Enriqué Steinberg, Fabiana Alejandra Rossi, Roberto Magliozzi, Laurensia Yuniati, Matteo Santucci, Mario Rossi, Daniele Guardavaccaro, Angela Lauriola

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Juliana Haydeé Enriqué SteinbergDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
Fabiana Alejandra RossiInstituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Av. Juan Domingo Perón 1500, B1629AHJ, Pilar, Argentina.
Roberto MagliozziHubrecht Institute-KNAW and University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.
Laurensia YuniatiHubrecht Institute-KNAW and University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.
Matteo SantucciDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy.
Mario RossiInstituto de Investigaciones en Medicina Traslacional (IIMT), CONICET-Universidad Austral, Av. Juan Domingo Perón 1500, B1629AHJ, Pilar, Argentina.ORCID 0000-0001-6349-8895
Daniele GuardavaccaroDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy. daniele.guardavaccaro@univr.it.ORCID 0000-0002-4517-1765
Angela LauriolaDepartment of Biotechnology, University of Verona, Strada Le Grazie 15, 37134, Verona, Italy. angela.lauriola@univr.it.ORCID 0000-0001-5286-8627
University of Verona · ITConsejo Nacional de Investigaciones Científicas y Técnicas · ARUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with metastasis, high recurrence rate, and poor survival. The basic helix-loop-helix transcription factor SHARP1 (Split and Hairy-related Protein 1) has been identified as a suppressor of the metastatic behavior of TNBC. SHARP1 blocks the invasive phenotype of TNBC by inhibiting hypoxia-inducible factors and its loss correlates with poor survival of breast cancer patients. Here, we show that SHARP1 is an unstable protein that is targeted for proteasomal degradation by the E3 ubiquitin ligase complex SCF

Indexed as

Triple Negative Breast NeoplasmsAnimalsBasic Helix-Loop-Helix Proteinsbeta-Transducin Repeat-Containing ProteinsHumansMicePhenotypeSynapsinsBasic Helix-Loop-Helix Proteinsbeta-Transducin Repeat-Containing ProteinsSynapsins

Identifiers

PMID37938564
PMCPMC10632515
OpenAlexW4388491092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.